ANXA10 sensitizes microsatellite instability-high colorectal cancer to anti-PD-1 immunotherapy via assembly of HLA-DR dimers by regulating CD74
Open Access
- 10 January 2025
- journal article
- research article
- Published by Springer Nature in Cell Biology and Toxicology
- Vol. 41 (1) , 1-23
Abstract
Background Microsatellite instability-high (MSI-H) metastatic colorectal cancer (CRC) patients are the dominant population in immune checkpoint blockade treatments, while more than half of them could not benefit from single-agent immunotherapy. We tried to identify the biomarker of MSI-H CRC and explore its role and mechanism in anti-PD-1 treatments. Tumor-specific MHC-II was linked to a better response to anti-PD-1 in MSI-H CRC and CD74 promoted assembly and transport of HLA-DR dimers. Methods The characteristic gene was screened by data analysis of single-cell and bulk transcriptome sequencing from public datasets. MSI-H CRC cells co-cultured with peripheral blood mononuclear cells and syngeneic model in C57BL/6 mice were performed to detect the sensitivity to anti-PD-1 treatments respectively. Results ANXA10 was identified as a characteristic gene of MSI-H CRC and its expression was obviously greater in MSI-H than MSS CRC. ANXA10 significantly sensitized MSI-H CRC to anti-PD-1 treatments in vitro and in vivo. Specifically, ANXA10 promoted HLA-DR dimers in and on the surface of MSI-H CRC by increasing CD74 expression. Besides, this work demonstrated that ANXA10 contributed to better clinical benefits with anti-PD-1 therapy in MSI-H CRC patients. Conclusions Our results provided a novel molecular marker ANXA10 to identify benefit population of MSI-H CRC for improving efficacy of anti-PD-1 and contributed to selection of treatment strategies.Keywords
This publication has 52 references indexed in Scilit:
- The multifaceted roles of the invariant chain CD74 — More than just a chaperoneBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2016
- Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapyNature Communications, 2016
- Evolving approach and clinical significance of detecting DNA mismatch repair deficiency in colorectal carcinomaSeminars in Diagnostic Pathology, 2015
- Annexin A10 expression in colorectal cancers with emphasis on the serrated neoplasia pathwayWorld Journal of Gastroenterology, 2015
- Annexin A10 expression correlates with serrated pathway features in colorectal carcinoma with microsatellite instabilityAPMIS, 2014
- The role of annexins in tumour development and progressionThe Journal of Pathology, 2008
- Interference with T cell receptor–HLA-DR interactions by Epstein–Barr virus gp42 results in reduced T helper cell recognitionProceedings of the National Academy of Sciences, 2003
- A pH-sensitive histidine residue as control element for ligand release from HLA-DR moleculesProceedings of the National Academy of Sciences, 2002
- Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunityProceedings of the National Academy of Sciences, 1997
- Defective major histocompatibility complex class II assembly, transport, peptide acquisition, and CD4+ T cell selection in mice lacking invariant chain expression.Journal of Experimental Medicine, 1993